[Glucose-insulin-potassium (GIK) solution: cardioprotective effects of insulin]. 2006

Eduardo Martín Rojas Pérez, and Pastor Luna Ortiz, and Xenia Serrano Valdez, and Bernardo J Fernández Rivera, and Alfredo de Micheli
Departamento de Anestesiologia, Instituto Nacional de Cardiología Ignacio Chávez. eredsp@yahoo.com.mx

In the Anesthesiology Department of the Instituto Nacional de Cardiología The medical staff uses the glucose insulin potassium i.v. for myocardial protection. The energy is dereived from lipidic beta oxidation, glucose breakdown and amino acid catabolism in mitochondria. In myocardial ischemia, from de aortic cross clamping, the metabolic myocardial substrates diminished as well as the energy produced by adenosine (ATP). During myocardial ischemia, an increase in long chain lipids emhances mitochondrial permeability, promotes depletion of citochrome C and lost of the capability of transmembrane regulation. In the hipoperfused myocardium, by coronary vasoconstriction, short chain fatty acids oxidation predominates, if fatty metabolism during reperfusion is elevated. More of them will enter [IBM1] the Krebs cycle and, as a consequence, less energy will be produced. The glucose-insulin-potassium solution provides the glucose needed by the myocardium in reperfusion conditions and protects the cellular membrane's integrity as well as pumps and ionic channels, it allows maintaining the action potential probably because ATP-depended channels block and prevent potassium loss, it reduces the cytosol calcium overload and prevent cardiac arrhythmias, preserves the sodium ATPasa pump avoiding the rise in cytosolic sodium; glucose prevents the production of free oxygen radicals. Fatty acids, during ischemia, are responsible for the metabolism and elevation of enzymes, such as acilcarnitine and acylcoenzime-A, which promote intracellular calcium overload and arrhythmias. The insulin has anti-inflammatory effects and anti-apoptoic effects. When blood glucose is controlled during the perioperative period the mortality is reduced.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002314 Cardioplegic Solutions Solutions which, upon administration, will temporarily arrest cardiac activity. They are used in the performance of heart surgery. Cardioplegic Solution,Solution, Cardioplegic,Solutions, Cardioplegic
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002985 Clinical Protocols Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy. Protocols, Clinical,Research Protocols, Clinical,Treatment Protocols,Clinical Protocol,Clinical Research Protocol,Clinical Research Protocols,Protocol, Clinical,Protocol, Clinical Research,Protocols, Clinical Research,Protocols, Treatment,Research Protocol, Clinical,Treatment Protocol
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

Eduardo Martín Rojas Pérez, and Pastor Luna Ortiz, and Xenia Serrano Valdez, and Bernardo J Fernández Rivera, and Alfredo de Micheli
September 1980, Critical care update,
Eduardo Martín Rojas Pérez, and Pastor Luna Ortiz, and Xenia Serrano Valdez, and Bernardo J Fernández Rivera, and Alfredo de Micheli
June 1977, Kokyu to junkan. Respiration & circulation,
Eduardo Martín Rojas Pérez, and Pastor Luna Ortiz, and Xenia Serrano Valdez, and Bernardo J Fernández Rivera, and Alfredo de Micheli
April 2010, Clinical science (London, England : 1979),
Eduardo Martín Rojas Pérez, and Pastor Luna Ortiz, and Xenia Serrano Valdez, and Bernardo J Fernández Rivera, and Alfredo de Micheli
June 1980, L'union medicale du Canada,
Eduardo Martín Rojas Pérez, and Pastor Luna Ortiz, and Xenia Serrano Valdez, and Bernardo J Fernández Rivera, and Alfredo de Micheli
January 1987, Progress in clinical and biological research,
Eduardo Martín Rojas Pérez, and Pastor Luna Ortiz, and Xenia Serrano Valdez, and Bernardo J Fernández Rivera, and Alfredo de Micheli
December 1980, The Central African journal of medicine,
Eduardo Martín Rojas Pérez, and Pastor Luna Ortiz, and Xenia Serrano Valdez, and Bernardo J Fernández Rivera, and Alfredo de Micheli
January 1975, Critical care medicine,
Eduardo Martín Rojas Pérez, and Pastor Luna Ortiz, and Xenia Serrano Valdez, and Bernardo J Fernández Rivera, and Alfredo de Micheli
October 1998, Acta physiologica Scandinavica,
Eduardo Martín Rojas Pérez, and Pastor Luna Ortiz, and Xenia Serrano Valdez, and Bernardo J Fernández Rivera, and Alfredo de Micheli
July 1990, No shinkei geka. Neurological surgery,
Eduardo Martín Rojas Pérez, and Pastor Luna Ortiz, and Xenia Serrano Valdez, and Bernardo J Fernández Rivera, and Alfredo de Micheli
July 1985, Critical care medicine,
Copied contents to your clipboard!